Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs02630417

Ligand	Ligand name	Chain	PDB	Tanimoto
IVS	3-HYDROXY-6-METHYL-4-(3-METHYL-2-(3-METHYL-2-(3-METHYL-BUTYRYLAMINO)-BUTYRYLAMINO)-BUTYRYLAMINO)-HEPTANOIC ACID ETHYL ESTER	A,B	1ME6	0.71
EP2	methyl N-[(2S)-4-{[(1S)-1-{[(2S)-2-carboxypyrrolidin-1-yl]carbonyl}-3-methylbutyl]amino}-2-hydroxy-4-oxobutanoyl]-L-leucylglycylglycinate	B	1SP4	0.7
SUJ	(2R,3R)-2-[(3S,6R)-3-AMINO-6-HYDROXY-2-OXOPIPERIDINYL]-3-HYDROXYBUTANOIC ACID	C,D	1OKX	0.71
HU4	TERT-BUTYL {(1S)-2-[(1R,2S,5R)-2-({[(1S)-3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]AMINO}CARBONYL)-7,7-DIMETHYL-6-OXA-3-AZABICYCLO[3.2.0]HEPT-3-YL]-1-CYCLOHEXYL-2-OXOETHYL}CARBAMATE	A,C	2OC7	0.72
U17	METHYL N-[(2S,3R)-3-AMINO-2-HYDROXYHEPTANOYL]-L-SERYL-L-LEUCINATE	A	2GGB	0.72
5FE	5,5,5-TRIFLUORO-3-HYDROXY-4-[2-(5,5,5-TRIFLUORO-3-HYDROXY-4-{3-METHYL-2-[3-METHYL-2-(3-METHYL-BUTYRYLAMINO)-BUTYRYLAMINO]-BUTYRYLAMINO}-PENTANOYLAMINO)-PROPIONYLAMINO]-PENTANOIC ACID METHYL ESTER	A,B	1XE5	0.71
ATI	N-(3-AMINO-2-HYDROXY-5-METHYLHEXANOYL)VALYLVALYLASPARTIC ACID	A	1Y0Y	0.71
OHN	N-3-OXO-DODECANOYL-L-HOMOSERINE LACTONE	E,F,G,H	2UV0	0.7
074	[PROPYLAMINO-3-HYDROXY-BUTAN-1,4-DIONYL]-ISOLEUCYL-PROLINE	A	1QDQ	0.76
AR9	(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide	A,B,C	3DV1	0.73
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A	3EMY	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A	2H6T	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1LS5	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1SME	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,C	1W6I	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1XDH	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	2QZX	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A	1IZE	0.7
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1M43	0.7
E6C	N-[1-HYDROXYCARBOXYETHYL-CARBONYL]LEUCYLAMINO-2-METHYL-BUTANE	A	1PPP	0.72
E6C	N-[1-HYDROXYCARBOXYETHYL-CARBONYL]LEUCYLAMINO-2-METHYL-BUTANE	A	1PE6	0.72
E6C	N-[1-HYDROXYCARBOXYETHYL-CARBONYL]LEUCYLAMINO-2-METHYL-BUTANE	A	1ITO	0.72
C99	{(2R)-2-[(1S,2R)-1-AMINO-2-HYDROXYPROPYL]-2-HYDROXY-4,5-DIOXOIMIDAZOLIDIN-1-YL}ACETIC ACID	A	2HCG	0.7
C6L	N-hexanoyl-L-homoserine	A	3DHA	0.73
C6L	N-hexanoyl-L-homoserine	A	3DHB	0.73